Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer
Bayer
Hoffmann-La Roche
Alume Biosciences, Inc.
Hoffmann-La Roche
Hoffmann-La Roche
AstraZeneca
Resilience
Astellas Pharma Inc
AstraZeneca
AstraZeneca
Federation Francophone de Cancerologie Digestive
Hoffmann-La Roche
M.D. Anderson Cancer Center
The Methodist Hospital Research Institute
Ain Shams University
University of California, San Diego
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Immune Oncology Research Institute
European Institute of Oncology
Hospices Civils de Lyon
Assiut University
Gangnam Severance Hospital
ERYtech Pharma
Bayer
Children's Oncology Group
Centre Jean Perrin
EMD Serono
Temple University
Medical University of Vienna
American Regent, Inc.
Jewish General Hospital
University of Sydney
Chinese PLA General Hospital
Tanta University
Sixth Affiliated Hospital, Sun Yat-sen University
Novartis
The First Affiliated Hospital of Zhengzhou University
Shanghai University of Traditional Chinese Medicine
The Hospital for Sick Children
European Institute of Oncology
University Hospital, Limoges
University of Chile
Ottawa Hospital Research Institute
Hoffmann-La Roche
All India Institute of Medical Sciences
Maastricht University Medical Center
Alliance for Clinical Trials in Oncology